BACKGROUND: Tazemetostat (EPZ-6438) is a selective inhibitor of the histone methyltransferase EZH2 and currently in clinical development for non-Hodgkin lymphoma and genetically defined tumors. PROCEDURES: Tazemetostat was tested against the Pediatric Preclinical Testing Program (PPTP) solid tumor xenografts using a dose of 400 mg/kg administered twice daily by oral gavage for 28 days. H3K27me3:H3 ratios were determined in control and treated tumors. RESULTS: Tazemetostat induced significant differences in event-free survival (EFS) distribution compared with control in nine of 30 (30%) of the xenografts studied. Significant differences in EFS distribution were observed in five of seven (71%) rhabdoid tumor xenograft lines compared with four of 23 (17%) nonrhabdoid xenograft lines (chi-square [χ2 ] test P = 0.006). Tazemetostat induced tumor growth inhibition meeting criteria for intermediate and high EFS treated-to-control (T/C) activity in two of 25 (8%) and one of 25 (4%) xenografts, respectively. Intermediate and high activity for the EFS T/C metric was observed exclusively among rhabdoid tumor xenografts (three of five rhabdoid tumor vs 0 of 22 nonrhabdoid tumors (χ² test P < 0.001). One rhabdoid tumor xenograft (G401) showed stable disease. For one rhabdoid tumor (G401), delayed tumor regression to tazemetostat was noted following 1 week of tumor growth. Tazemetostat induced significant reduction of H3K27me3 levels in the majority of tumors compared with controls. CONCLUSIONS: Tazemetostat demonstrated significant antitumor activity in rhabdoid tumor models but showed no consistent activity against any other histology. Tazemetostat reduced H3K27me3 levels irrespective of tumor response. Further preclinical testing to evaluate tazemetostat in combination with other anticancer agents is warranted.
BACKGROUND:Tazemetostat (EPZ-6438) is a selective inhibitor of the histone methyltransferase EZH2 and currently in clinical development for non-Hodgkin lymphoma and genetically defined tumors. PROCEDURES: Tazemetostat was tested against the Pediatric Preclinical Testing Program (PPTP) solid tumor xenografts using a dose of 400 mg/kg administered twice daily by oral gavage for 28 days. H3K27me3:H3 ratios were determined in control and treated tumors. RESULTS:Tazemetostat induced significant differences in event-free survival (EFS) distribution compared with control in nine of 30 (30%) of the xenografts studied. Significant differences in EFS distribution were observed in five of seven (71%) rhabdoid tumor xenograft lines compared with four of 23 (17%) nonrhabdoid xenograft lines (chi-square [χ2 ] test P = 0.006). Tazemetostat induced tumor growth inhibition meeting criteria for intermediate and high EFS treated-to-control (T/C) activity in two of 25 (8%) and one of 25 (4%) xenografts, respectively. Intermediate and high activity for the EFS T/C metric was observed exclusively among rhabdoid tumor xenografts (three of five rhabdoid tumor vs 0 of 22 nonrhabdoid tumors (χ² test P < 0.001). One rhabdoid tumor xenograft (G401) showed stable disease. For one rhabdoid tumor (G401), delayed tumor regression to tazemetostat was noted following 1 week of tumor growth. Tazemetostat induced significant reduction of H3K27me3 levels in the majority of tumors compared with controls. CONCLUSIONS:Tazemetostat demonstrated significant antitumor activity in rhabdoid tumor models but showed no consistent activity against any other histology. Tazemetostat reduced H3K27me3 levels irrespective of tumor response. Further preclinical testing to evaluate tazemetostat in combination with other anticancer agents is warranted.
Authors: Christopher J Sneeringer; Margaret Porter Scott; Kevin W Kuntz; Sarah K Knutson; Roy M Pollock; Victoria M Richon; Robert A Copeland Journal: Proc Natl Acad Sci U S A Date: 2010-11-15 Impact factor: 11.205
Authors: Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado Journal: Nature Date: 2012-01-29 Impact factor: 49.962
Authors: C Bödör; C O'Riain; D Wrench; J Matthews; S Iyengar; H Tayyib; M Calaminici; A Clear; S Iqbal; H Quentmeier; H G Drexler; S Montoto; A T Lister; J G Gribben; A Matolcsy; J Fitzgibbon Journal: Leukemia Date: 2011-01-14 Impact factor: 11.528
Authors: Ping Zhang; Mark C de Gooijer; Levi C M Buil; Jos H Beijnen; Gang Li; Olaf van Tellingen Journal: Int J Cancer Date: 2015-04-24 Impact factor: 7.396
Authors: Shivani Garapaty-Rao; Christopher Nasveschuk; Alexandre Gagnon; Eric Y Chan; Peter Sandy; Jennifer Busby; Srividya Balasubramanian; Robert Campbell; Feng Zhao; Louise Bergeron; James E Audia; Brian K Albrecht; Jean-Christophe Harmange; Richard Cummings; Patrick Trojer Journal: Chem Biol Date: 2013-10-31
Authors: Joshua L Cohen; Nateka L Jackson; Mary E Ballestas; William M Webb; Farah D Lubin; Sarah M Clinton Journal: Eur J Neurosci Date: 2017-07-06 Impact factor: 3.386
Authors: Jeannie M Camarillo; Suchitra Swaminathan; Nebiyu A Abshiru; Jacek W Sikora; Paul M Thomas; Neil L Kelleher Journal: J Am Soc Mass Spectrom Date: 2019-07-08 Impact factor: 3.109
Authors: Lindsey M Hoffman; Elizabeth Anne Richardson; Ben Ho; Ashley Margol; Alyssa Reddy; Lucie Lafay-Cousin; Susan Chi; Irene Slavc; Alexander Judkins; Martin Hasselblatt; Franck Bourdeaut; Michael C Frühwald; Rajeev Vibhakar; Eric Bouffet; Annie Huang Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: Serap Erkek; Pascal D Johann; Martina A Finetti; Yiannis Drosos; Hsien-Chao Chou; Marc Zapatka; Dominik Sturm; David T W Jones; Andrey Korshunov; Marina Rhyzova; Stephan Wolf; Jan-Philipp Mallm; Katja Beck; Olaf Witt; Andreas E Kulozik; Michael C Frühwald; Paul A Northcott; Jan O Korbel; Peter Lichter; Roland Eils; Amar Gajjar; Charles W M Roberts; Daniel Williamson; Martin Hasselblatt; Lukas Chavez; Stefan M Pfister; Marcel Kool Journal: Cancer Cell Date: 2018-12-27 Impact factor: 31.743